George Yancopoulos (Brendan McDermid/Reuters/Alamy)
February 4, 2022 01:03 PM EST
R&D
Pharma

Re­gen­eron looks to George Yan­copoulos' R&D arm — and part­ners — in hunt for its next big cash cows

John Carroll

Editor & Founder

Re­gen­eron R&D chief and co-founder George Yan­copou­los has nev­er been shy about tout­ing the com­pa­ny’s re­search ca­pa­bil­i­ties — or am­bi­tions. But then, he’s al­so a stand­out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times